Low Potassium, Higher Diabetes Risk? A Surprising Clue From Heart Failure Research

Low potassium is usually viewed through a cardiovascular lens, especially in patients with heart failure. However, emerging evidence suggests clinicians may have another reason to pay attention. New research examining the relationship between hypokalemia and diabetes risk found that lower serum potassium levels were associated with a greater risk of developing diabetes among people with heart failure with mildly reduced or preserved ejection fraction.

The finding does not prove that low potassium causes diabetes. Still, it adds to decades of research connecting potassium balance with insulin secretion and glucose regulation. As a result, an ordinary electrolyte measurement could offer clues about metabolic health that deserve closer investigation.

Table of Contents

• What the new heart failure research found
• Why potassium may affect glucose regulation
• Heart failure treatments and potassium levels
• What the findings mean for diabetes prevention
• Conclusion
• Frequently Asked Questions

Low Potassium and New-Onset Diabetes in Heart Failure

The latest evidence comes from an analysis of the FINEARTS-HF trial involving patients with heart failure and mildly reduced or preserved ejection fraction. Researchers examined 3,224 participants without diabetes at baseline. Their mean age was 72 years, and their average HbA1c was 5.7%.

During a median follow-up of 2.7 years, lower time-updated serum potassium was associated with a higher risk of new-onset diabetes. Specifically, each 0.5 mmol/L decrease in potassium was associated with a 19% higher adjusted risk of developing diabetes.

The findings were first reported in an American Diabetes Association abstract and have since been reported in Diabetes Care.

Importantly, the study shows an association rather than proof of cause and effect. Patients with heart failure often have several overlapping factors that influence both potassium and glucose. Kidney function, medications, disease severity, diet, and other metabolic conditions may all play a role.

Nevertheless, the results strengthen an existing biological argument. Potassium is not simply an electrolyte needed for cardiac electrical activity. It also participates in the cellular processes involved in insulin release.

Why Low Potassium Could Affect Glucose Regulation

The connection between potassium and glucose metabolism is not new. In fact, experimental research has shown that potassium depletion can reduce the pancreatic beta cell response to rising glucose.

Beta cells rely partly on potassium channels to control the sequence of events that triggers insulin release. Therefore, disrupted potassium balance may interfere with the body’s ability to release enough insulin after glucose levels rise.

The National Institutes of Health Office of Dietary Supplements notes that potassium is required for insulin secretion and that hypokalemia can impair insulin secretion and potentially contribute to glucose intolerance.

Earlier experimental studies provide additional support. When researchers deliberately induced potassium depletion in people with normal glucose tolerance, insulin release in response to glucose declined. Moreover, some studies found that correcting potassium depletion improved the insulin response.

Population research has also linked lower serum potassium with higher rates of impaired fasting glucose, insulin resistance, and type 2 diabetes. However, these associations do not mean potassium supplementation will prevent diabetes.

That distinction matters. Low potassium and increased diabetes risk may share common drivers rather than a simple cause-and-effect pathway. Still, the biological evidence makes the association plausible enough to warrant further study.

Heart Failure Medications May Complicate the Picture

Heart failure creates a particularly interesting setting for studying potassium because several commonly used treatments can change serum potassium levels.

Loop diuretics, for example, may increase urinary potassium losses. Other therapies can have the opposite effect. Mineralocorticoid receptor antagonists may raise potassium, particularly in people with impaired kidney function.

The FINEARTS-HF analysis is especially notable because the original trial evaluated finerenone, a nonsteroidal mineralocorticoid receptor antagonist. Researchers therefore also investigated whether changes in potassium might help explain treatment effects on new-onset diabetes.

Yet medication effects are only part of the story. Potassium and glucose regulation have previously intersected in studies involving thiazide diuretics.

A quantitative review published in Hypertension evaluated 59 clinical trials and found an inverse relationship between changes in potassium and glucose during thiazide treatment. In other words, larger potassium declines tended to accompany larger glucose increases.

Earlier analysis from the Systolic Hypertension in the Elderly Program also produced a striking observation. Each 0.5 mEq/L decline in serum potassium was associated with a 45% higher adjusted risk of diabetes during the studied period.

However, not every study has confirmed this relationship. Therefore, clinicians should avoid assuming that correcting potassium automatically lowers diabetes risk.

Could Potassium Become a Metabolic Risk Marker?

For now, potassium should not be treated as a stand-alone diabetes screening test. Established measures such as fasting glucose and HbA1c remain central to identifying prediabetes and diabetes.

Even so, the new findings may encourage clinicians to look differently at persistently low or falling potassium levels. In a patient already at high metabolic risk, hypokalemia could potentially become one additional signal prompting closer attention to glucose status.

This possibility may be especially relevant for people with heart failure. These patients often have multiple cardiometabolic conditions and receive therapies that alter kidney function, fluid balance, and electrolytes. Consequently, changes in potassium should always be interpreted within the larger clinical picture.

The findings also do not justify routine potassium supplementation for diabetes prevention. Too much potassium can be dangerous, particularly for people with kidney disease or those taking medications that increase serum potassium.

Instead, clinicians should identify the reason for hypokalemia and manage it appropriately. Medication exposure, gastrointestinal losses, dietary factors, kidney function, and other medical conditions may need consideration.

Patients concerned about low potassium, blood glucose, or diabetes risk should discuss testing and treatment with a qualified healthcare professional. Future randomized studies will be needed to determine whether actively correcting low potassium changes the likelihood of developing diabetes.

Conclusion

The emerging evidence linking low potassium with diabetes risk adds another layer to the relationship between cardiovascular and metabolic health. In the recent FINEARTS-HF analysis, lower serum potassium was associated with a greater risk of new-onset diabetes among patients with heart failure and mildly reduced or preserved ejection fraction.

There is also biological support for the observation because potassium participates in pancreatic beta cell function and insulin secretion. Previous research involving potassium depletion and diuretic therapy has reported similar links with impaired glucose regulation.

However, an association is not proof that hypokalemia causes diabetes. Nor does current evidence establish potassium supplementation as a diabetes prevention strategy.

For clinicians, the most useful message may be simpler: potassium could carry metabolic information in addition to its familiar cardiovascular significance. Whether it eventually becomes a practical marker of diabetes risk will depend on further prospective and interventional research.

Frequently Asked Questions

Can hypokalemia cause diabetes?

Current evidence does not establish hypokalemia as a direct cause of diabetes. However, low potassium can impair insulin secretion, and several studies have associated lower potassium levels with greater diabetes risk.

How does low potassium affect insulin?

Potassium helps pancreatic beta cells respond to glucose and release insulin. Potassium depletion may interfere with this process, potentially contributing to poorer glucose tolerance.

What did the heart failure study find?

Among 3,224 FINEARTS-HF participants without diabetes at baseline, each 0.5 mmol/L decrease in time-updated serum potassium was associated with a 19% higher adjusted risk of new-onset diabetes during a median 2.7 years of follow-up.

Should people take potassium to prevent diabetes?

No. Current evidence does not support taking potassium supplements specifically to prevent diabetes. Excess potassium can also be dangerous, especially in people with kidney disease or those taking potassium-raising medications.

Should patients with hypokalemia have their glucose checked?

Glucose testing depends on the patient’s overall risk profile and clinical situation. However, persistent hypokalemia combined with other diabetes risk factors may provide another reason for clinicians to consider metabolic evaluation and appropriate follow-up.

This content is not medical advice. For any health issues, always consult a healthcare professional. In an emergency, call 911 or your local emergency services.